



| Form PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | | | Complete if Known | | | |
|---|----------|---|------------|--------------------------|-----------------------|----------|------------------------------|
| LIST OF INFORMATION CITED BY APPLICANT (Use as many sheets as necessary) | | | | Application Number | 10/650,260 | | |
| | | | | Filing Date | August 27, 2003 | | |
| | | | | First Named Inventor | Poynard | | |
| | | | | Group Art Unit | Unassigned | | |
| | | | | Examiner Name | Unassigned | | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| Examiner's Initials | Cite No. | Document No. | Date | Name | Class | Subclass | Filing Date (if appropriate) |
| JSB | *A1 | 5,935,798 | 08/10/1999 | Price et al. | 435 | 7.23 | |
| JSB | *A2 | 4,312,853 | 01/26/1982 | Timpl | 424 | 1 | |
| FOREIGN PATENT DOCUMENTS | | | | | | | |
| Examiner's Initials | Cite No. | Foreign Patent Document Country Code-Number-Kind Code | Date | Name | Translation Yes/No | | |
| JSB | *A3 | EP 0 911 343 A2 | 04/28/1999 | Tosoh Corporation | | | |
| JSB | *A4 | WO 01/86304 A2 | 11/15/2001 | Bayer Aktiengesellschaft | | | |
| NON-PATENT DOCUMENTS | | | | | | | |
| Examiner's Initials | Cite No. | Non-Patent Citations (include Author, Title, Publisher, Relevant Pages, Date and Place of Publication) | | | | | |
| JSB | *A5 | Bedossa et al., "Apolipoprotein AI is a Serum and Tissue Marker of Liver Fibrosis in Alcoholic Patients." <i>Alcohol Clin. Exp. Res.</i> 13(6):829-833 (November/December 1989) | | | | | |
| JSB | *A6 | Gabielli et al., "Serum laminin and type III procollagen in chronic hepatitis C. Diagnostic value in the assessment of disease activity and fibrosis." <i>Clin. Chim. Acta</i> 265:21-31 (1997) | | | | | |
| JSB | *A7 | Guechot et al., "Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis." <i>Clin Chem.</i> 42(4):558-563 (1996) | | | | | |
| JSB | *A8 | Johnston, "Special Considerations in Interpreting Liver Function Tests." <i>Am. Fam. Physician</i> pp. 1-11 (April 15, 1999) www.aafp.org/afp/990415ap/2223.html (Print Date of February 8, 2002) | | | | | |
| JSB | *A9 | Kasahara et al., "Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. Relationship to interferon response." <i>J. Hepatol.</i> 26(3):574-583 (March 1997) | | | | | |
| JSB | *A10 | Kropf et al., "Efficacy of Serum Laminin Measurement for Diagnosis of Fibrotic Liver Diseases." <i>Clin. Chem.</i> 34(10):2026-2030 (1988) | | | | | |
| JSB | *A11 | Naveau et al., "Alpha-2-Macroglobulin and Hepatic Fibrosis. Diagnostic Interest." <i>Dig. Dis. Sci.</i> 39(11):2426-2432 (November 1994) | | | | | |
| JSB | *A12 | Oberti et al., "Noninvasive Diagnosis of Hepatic Fibrosis or Cirrhosis." <i>Gastroenterology</i> 113(5):1609-1616 (November 1997) | | | | | |
| JSB | *A13 | Pilette et al., "Histopathological evaluation of liver fibrosis: quantitative image analysis vs semi-quantitative scores. Comparison with serum markers." <i>J. Hepatol.</i> 28(3):439-446 (March 1998) | | | | | |
| no copy provided | *A14 | Poynard and Bedossa, "Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus." <i>METAVIR and CLINIVIR Cooperative Study Groups. J. Viral Hepat.</i> 4(3):199-208 (May 1997) | | | | | |



ATTORNEY DOCKET NO. 03225.0001U2
APPLICATION NO. 10/650,260
SHEET 2 OF 2

| | | |
|--|------|--|
| JSB | *A15 | Poynard et al., "Natural history of liver fibrosis progression in patients with chronic hepatitis C." The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC Groups. <i>Lancet</i> 349(9055):825-832 (March 22, 1997) |
| JSB | *A16 | Teare et al., "Comparison of serum procollagen III peptide concentrations and PGA index for assessment of hepatic fibrosis." <i>Lancet</i> 342:895-898 (October 9, 1993) |
| JSB | *A17 | Wong et al., "Serum hyaluronic acid is a useful marker of liver fibrosis in chronic hepatitis C virus infection." <i>J. Viral Hepat.</i> 5:187-192 (May 1998) |
| | | |
| | | |
| | | |
| | | |
| | | |
| Examiner Signature: /John S. Brusca/ Date Considered: 06/25/2006 | | |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | |